ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1113

Inflammatory Biomarkers Improve Prediction of Sertraline Treatment Response in CKD

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Gregg, L Parker, University of Texas Southwestern, Dallas, Texas, United States
  • Carmody, Thomas, University of Texas Southwestern, Dallas, Texas, United States
  • Le, Dustin, University of Texas Southwestern, Dallas, Texas, United States
  • Trivedi, Madhukar, University of Texas Southwestern, Dallas, Texas, United States
  • Hedayati, Susan, University of Texas Southwestern, Dallas, Texas, United States

Inflammation may mediate depression, and CKD is associated with elevated inflammatory markers and depression prevalence. We studied whether baseline inflammation predicts treatment response to sertraline in individuals with CKD and depression.


In 193 participants with stage 3-5 CKD and depression randomized to sertraline or placebo in the double-blind Chronic Kidney Disease Antidepressant Sertraline Trial (CAST), we measured baseline albumin, pre-albumin, interleukin-6 (IL-6), and high sensitivity C-reactive protein (hsCRP). Outcomes were a ≥3-point decrease (improvement) and ≥50% decrease (response) in depressive symptoms, assessed by the Clinician-Rated 16-Item Quick Inventory of Depression Symptomatology (QIDS). Logistic regression measured associations of inflammatory markers with outcomes after covariate adjustment. Inflammatory marker x treatment interaction P<.1 was considered significant. The areas under the curve (AUC) for nested models predicting response were compared using non-parametric tests.


Mean age was 58±13 years, 58% were Black, 42% White, and 18% Hispanic. HsCRP correlated with baseline QIDS score (r=.19, P<.05). In the sertraline group, hsCRP was higher in those who did vs. did not achieve improvement, median (IQR): 5.0 (1.7-8.6) mg/L vs. 1.4 (0.6-3.7), P=.005, and response, 5.0 (2.0-14.6) vs. 2.7 (0.8-6.0), P=.03. A 1 log-unit increase of hsCRP independently predicted a differential degree of improvement and response to sertraline vs. placebo (Table). Baseline QIDS, eGFR, age, diabetes, site, and hsCRP (highest tertile) predicted sertraline response, AUC (95% CI) .71 (.58, .85). Addition of albumin and pre-albumin (lowest tertile) and IL-6 (highest tertile) improved the AUC to .82 (.72, .92), P=.02 (Figure).


Higher baseline hsCRP was independently associated with depressive symptom improvement and response to sertraline. Inflammatory biomarkers may identify CKD patients more likely to benefit from sertraline.

OutcomeAll participants
aOR (95% CI)
aOR (95% CI)
aOR (95% CI)
hsCRP x treatment group interaction P value
Improvement1.32 (1.00, 1.74)1.67 (1.11, 2.52)0.92 (0.63, 1.34)0.03
Response1.29 (0.97, 1.71)1.56 (1.08, 2.26)0.90 (0.58, 1.39)0.06


  • NIDDK Support